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Rationale: Epilepsy surgery is a standard of care in the treatment of medically intractable epilepsy, but is underutilised. We
describe the results of epilepsy surgery and the referral patterns at a referral epilepsy programme.
Methods: We reviewed the outcome of epilepsy surgery performed at the University of South Florida and Tampa General Hospital
epilepsy programme for the years 2000 and 2001. The typical presurgical evaluation included clinical evaluation, EEG-video
monitoring, MRI with dedicated epilepsy protocol, PET, SPECT, neuropsychological testing and Wada testing. We used the
Engel outcome classification, and focused on the referral information to determine how and when in the course of their illness
patients arrive at a referral epilepsy centre.
Results: In the 2-year period (2000–2001), a total of 36 epilepsy surgeries were performed. Twenty-nine temporal lobectomies, six
extratemporal resections and one corpus callosotomy. Ages varied from 17 to 65 years. Overall results were: 30 (83%) seizure-free
[class I], 5 (17%) rare seizures or almost seizure-free [class II] and 1 no improvement. Of the 29 temporal lobectomies, 27 (93%)
are completely seizure-free [class I] and 2 (7%) are >90% improved [class II]. Duration of seizures before being seen at the
epilepsy centre averaged 18 years (range 2–58 years). Twenty-two (61%) were sent by their neurologists, while 14 (39%) came
self-referred without having discussed surgery with their neurologists. Five (14%) were specifically advised by their neurologist
to not consider surgery. Two had participated in clinical trials of antiepileptic drugs (AEDs) before being seen at the epilepsy
centre.
Conclusions: Epilepsy surgery has high efficacy and very low morbidity. Yet, there continues to be a long delay in the referral
of patients to the epilepsy centre, suggesting that surgery for epilepsy is underutilised.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Epilepsy is one of the commonest neurologic diseases,
affecting 1% of the population. It is well established
that 20–30% of patients with chronic seizures are
not adequately controlled by medications1–4, and that
epilepsy surgery is standard of care1, 3, 5 in this situ-
ation. However, surgery for epilepsy is underutilised
and it is believed that physicians fail to refer patients
or refer them too late4.
We herein describe the results of epilepsy surgery
at a single referral epilepsy programme, and examine
the referral patterns and time frames to determine how
and when in the course of their illness patients arrive
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at a referral epilepsy centre and undergo surgery. We
then discuss possible ways to improve accessibility of
patients to epilepsy surgery.
METHODS
We reviewed the outcome of epilepsy surgery per-
formed at our referral epilepsy programme (University
of South Florida and Tampa General Hospital). We in-
cluded all cases of epilepsy surgery operated on by a
single (epilepsy) neurosurgeon (FLV) during a 2-year
period (January 1, 2000 to December 31, 2001), not
including vagus nerve stimulator (VNS).
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The typical presurgical evaluation included clinical
evaluation, EEG-video monitoring, MRI with dedi-
cated epilepsy protocol, PET or SPECT scan, neu-
ropsychological testing and Wada testing. A relatively
standardised algorithm was generally followed1. We
used the Engel outcome classification6.
RESULTS
In the 2-year period, a total of 36 epilepsy surgeries
were performed: 29 temporal lobectomies, 6 extratem-
poral resections and 1 corpus callosotomy. Ages var-
ied from 17 to 65 years. Of the 35 resections, 4 were
preceded by invasive EEG (subdural in 3 and epidural
in 1).
Efficacy
Overall results were: 30 (83%) seizure-free [class I],
5 (17%) rare seizures or almost seizure-free [class II]
and 1 no improvement. Of the 29 temporal lobec-
tomies, 27 (93%) are completely seizure-free [class I]
and 2 (7%) are >90% improved [class II].
Safety and complications
One intraoperative lacunar stroke occurred in a
65-year-old woman, which resulted in left upper ex-
tremity monoparesis. Interestingly, despite her new
deficit, this patient felt she was better off after surgery,
as she had a seizure-free outcome and no longer had
to visit the emergency department on a regular basis.
Two patients had a postoperative superficial infection
that was successfully treated with antibiotics.
How do patients end up at the epilepsy centre?
Duration of seizures before being seen at the
epilepsy centre averaged 18 years (range 2–58 years).
Twenty-two (61%) were sent by their neurologists,
while 14 (39%) came self-referred without having
discussed surgery with their neurologists. Five (14%)
were specifically advised by their neurologist to not
consider surgery. Two patients had participated in
clinical trials of antiepileptic drugs (AEDs) before
being seen at the epilepsy centre.
DISCUSSION
As in other series, temporal lobectomies were by far
the most common operation. Also similar to previous
reports, outcome was excellent.
We found a long delay in the referral of patients to
the epilepsy centre. This is comparable to a recent
series of 89 temporal lobectomies, which reported
a mean duration of epilepsy of 18.8 years prior to
surgery despite a median seizure frequency of 8 per
month7. In that study, some of the delay may have
been related to the presurgical evaluation, whereas
we measured the delay to the first visit at the epilepsy
centre (epileptologist). Another important and related
finding was that a significant proportion (39%) of
patients were not sent by their neurologists and had
not been given an opportunity to discuss this option.
In fact some (14%) were specifically advised against
surgery and given dissuasive information about
epilepsy surgery, especially about serious neurologic
complications. This has not been previously reported,
but is critical, since it likely results in many surgical
candidates never accessing an epilepsy centre and is
likely an important cause for the underutilisation of
epilepsy surgery.
The reasons for this poor referral patterns are unclear
and probably diverse. One possible cause is lack of
familiarity (of neurologists) with the efficacy and low
morbidity of epilepsy surgery. As a result, they may
have misconceptions and convey lack of efficacy or,
more often, risk of severe postoperative deficits, as was
the case for several of our patients. Yet, there is abun-
dant literature available, including entire textbooks
dedicated to the topic of epilepsy surgery8, 9. There
are even published (but little known) guidelines on the
time frames for referring patients to an epilepsy cen-
tre, which state that referral to a specialised epilepsy
centre is appropriate if seizure control is not achieved
within 9 months by the general neurologist10, 11.
Another problem is defining intractability, or how
many drugs should be tried before declaring a patient
medically intractable, which remains an individual
and variable decision. Nevertheless, it is now known
that the chances of seizure control decline rapidly
after the first few AED trials. Whether with classic
AEDs12, or newer generation AEDs13, only 9–14%
of patients eventually become controlled with drugs
after the first one fails. This in fact is even largely
true in children14. An increasingly used definition of
medical intractability, at least in adults, is persistent
seizures despite 2 years and two maximally tolerated
AED trials12, 15. In this situation, nonpharmacologic
options should be examined early rather than as a last
resort1, 3, 4, 7, 13. A recently published expert-opinion
consensus on the treatment of epilepsy was also in
agreement with this16. A relatively common situation
is that acceptable seizure control is obtained at the ex-
pense of severe side effects that impair quality of life
(e.g. patients report extreme fatigue, clouded thinking,
dizziness, etc.). This in fact constitutes drug failure,
but this concept is often overlooked, and patients are
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often taught that no alternatives exist outside of ‘more
medications’.
Another possible explanation is that general neurol-
ogists are not equipped to identify potential surgical
candidates. However, the fact that our outcome was
excellent and comparable to other large series2, 7 indi-
cate that these patients did not present any unusual dif-
ficulties in order to be identified as potential surgical
candidates. In fact, most had straightforward mesial
temporal sclerosis, which should be relatively easy to
identify on clinical grounds4, 17.
Finally, a more concerning possible reason may
be the desire for physicians to ‘keep their patients’
for a variety of reasons, including to enroll some in
industry-sponsored clinical trials.
The consequences of years of ongoing seizures
are well known, and include severe psychosocial
consequences4, 18 that may not resolve if seizure-free
status is achieved too late. Postoperative outcome also
appears to be adversely affected by a longer duration
of chronic seizures19. In addition, mesial temporal
lobe epilepsy may well be a progressive disorder4,
and is particularly likely to become intractable20. Fi-
nally, it has been argued that the risk of death from
ongoing seizures is higher than that from a typical
temporal lobectomy4, 7, 21.
Whatever the reasons for this poor referral pattern,
epilepsy surgery is standard of care when medications
fail, and thus it can be argued that not referring patients
with intractable seizures to the epilepsy centre may
raise issues of ethics. Failing to offer the possibility
of (and evaluation for) nonpharmacologic treatments
(i.e. surgery, VNS, or ketogenic diet) amounts to with-
holding information, and as such violates the principle
of autonomy (letting patients decide if they are inter-
ested in these options). It also violates the principle of
beneficence (providing the best available treatment).
Specifically, we believe that it is certainly unethical
to enroll patients for investigational treatments (e.g.
drug studies) before at least offering an evaluation at a
comprehensive (surgical) epilepsy centre. Several pa-
tients in this series clearly stated that they were never
offered nonpharmacologic options, and two were en-
rolled in a drug study.
We believe that this is a serious problem. Epilepsy is
one area of neurology where patients can actually be
cured and have their lives radically changed. Perhaps
general neurologists believe that these patients are
rare. Based on the epidemiology (prevalence of 1%)
and natural history (20% intractable) of epilepsy, there
are probably as many potential surgical candidates as
patients with multiple sclerosis! Thus, every general
neurology practice likely sees these patients, and one
that never refers to the epilepsy centre is in all like-
lihood failing to identify them. A recent randomised
trial of surgery in patients with poorly controlled tem-
poral lobe epilepsy21 strongly argues for the superior-
ity of surgery over medical therapy in terms of seizure
control, quality of life, rates of employment and school
attendance. Another upcoming randomised controlled
US trial may help further4, and many patients could
certainly testify that their lives have been changed22.
Education about epilepsy surgery is seriously needed,
both to the public and to health care professionals,
and including neurologists, as epilepsy surgery con-
tinues to be underutilised. As mentioned earlier, the
only guidelines for referral to epilepsy centres were
published in a subspecialty journal10, 11. Such guide-
lines should be more widely published (e.g. by the
AAN) in order to be available to the general neurolo-
gist, and specific emphasis should be placed on when
and whom to refer to the epilepsy centre.
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